Medical innovation through high-impact metabolic modifiers
Therapies in Join Diseases
The joint diseases Osteoarthritis (OA) and Tendinopathies are
still in search of efficient pharmacologic treatments.
TP7193 is an emerging disease-modifier drug outperforming in these widespread medical needs.
Possible spin-out is pursued to attain the clinical Proof-of-Concept on major indications.
Treatment of Dementia
Vascular dementia (VaD) is a unmet medical need while aggravates Alzheimer’s and other dementiae while
no therapeutic options are presently available.
TP7193SL is designed as delivery-optimized, disease-modifying candidate VaD
drug to prevent or rescue neurovascular derangement in pre- and dementia patients.
Innovation in ObGyn, and more
Ten years of experimental and regulatory works on the regenerative space ended-up with innovative medical devices for poorly met WH’s disorders.
Partners are sought since limited investments will enable the marketing expansion to generate significant therapeutic and financial values.
Iron homeostasis modifiers
Novel approaches via Fe-modulation
Research on Iron pharmacology in close cooperation with the University of Milan produced at least a ready-to-market product (Fextract). Iron modulation provides favorable outcomes in skin and gastrointestinal tissues, inter-alia. This pipeline could be divested to refocus on other regenerative therapies
Tixupharma in brief
Founded in 2013 by Carlo Ghisalberti, Tixupharma holds the goal to develop novel therapies in the chronic-degenerative space.
Tixupharma operated via open-source model within Dept. of Biomed Science for Health at the University of Milan and external institutions on new medicines for underserved, or even fully unmet, medical needs
A state-of-art platform based on epigenetic (autocrine) molecule and its clinical application for several chronic disorders, aims at becoming the next --> REGENERATIVE THERAPEUTICS, Ubigel in ObGyn, Epigel in Joint Diseases; Reline in Vascular Dementia.
Joint diseases: Osteoarthritis (OA) and Tendinopathies (TP) are still in search of efficient pharmacology. TP7193 is a candidate disease-modifying OA drug (DMOAD) and TP therapeutic by fast-acting (2-4 weeks) in discontinuous dose
Historical experience in Iron chemistry and related niche therapies --> IRON HOMEOSTASIS MODIFIERS, Iron Deficiency Anemia and next
R&D assets span from concepts to ready-to-market medicines, grounded on a robust IP plus regulatory package
Tixupharma Srl SU
Via Belvedere 10
24016 San Pellegrino Terme (BG)
Tel: +39 348 7454645
Via Luigi Mangiagalli 31
20133 Milano - IT
@General Pathology, SCIBIS Dept
University of Milan